

SYNTHESIS, IN-SILICO AND IN-VITRO SCREENING OF NOVEL PYRROLYL THIAZOLIDINONE DERIVATIVES AS POTENT ANTI-TUBERCULAR AGENTS

Shivani G Shah, Pradeep Kumar M.R.*

Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Vidyanagar, Hubli-580031(A Constituent unit of KAHER, Belagavi)

Corresponding author: Email- pradeepmrpk@yahoo.co.in

Abstract

A series of novel Pyrrolyl thiazolidinone derivatives were synthesized by the reaction between Pyrrolyl hydrazide in presence of substituted aldehyde, ethanol to obtain Pyrrolyl Schiff Base; Further Pyrrolyl Schiff Base in presence of thioglycolic acid and Benzene refluxed for 12hr to yield Pyrrolyl thiazolidinone derivatives(4a-c). Through FT-IR, ¹H NMR, ¹³C NMR and Mass Spectroscopy the synthesized compound were successfully confirmed, Pyrrolyl derivatives was thoroughly analyzed for their in-vitro antitubercular activity against Mycobacterium tuberculosis using H₃₇Rv Strains by using Microplate Almar Blue Assay (MABA) method, Isoniazid and Rifampicin used as reference standard drugs. Among all the synthesized compound 4b shows good activity when compared to standard drugs.

In-Silico, Molecular Docking Studies were carried out on newly synthesized compound Pyrrolyl thiazolidinone Derivatives(4a-c) using PyRx and Discovery studio software which shows the vital interaction and binding affinity.

Keywords: Pyrrole, IR, NMR, Molecular Docking, MABA Method.

Introduction

Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis it is the worlds second common cause of death from infectious disease after AIDS ⁽¹⁾. TB is a systemic disease with typical Pulmonary manifestation, which is transmitted from person to person by airborne bacteria⁽²⁾

Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microtic, Mycobacterium canetti, Mycobacterium tuberculosis are five closely related Mycobacteria that produces the pandemic illness⁽³⁾. Mycobacterium tuberculosis has been the major causative agent of tuberculosis, a disease that affects the lungs, referred as pulmonary TB and some other part as well, referred as extrapulmonary TB^(3,4) Factors that increase the risk of developing active TB include undernutrition, alcohol consumption, smoking, diabetics. TB which resist to both isoniazid and rifampicin, the most powerful anti-TB drugs is called as MDR-TB 2⁽⁵⁾

First line and Second line drugs; The first line drugs that include Isoniazid, Rifampicin, Ethambutol and streptomycin. The first line drugs combines with greatest level of efficacy with acceptable degree of toxicity and also responsible for the adverse reaction. Second line drugs include Kanamycin, Cyclosterin, Ethionamide and Quinoline, Second line drugs shows Potentially nephrotoxicity⁽⁶⁾ According to the WHO; In 2022, around 2 billion people were infected with TB, In 2018, 1.6 million TB-related deaths and In 2017, 10 million new cases of TB were observed.^(3,7,8)

It has become crucial for TB control to create a quick diagnostic test that can differentiate between active TB and LTBI or active TB and non-active TB, as well as detect M. tb infection.⁽⁹⁾

Tuberculosis is repeatedly diagnose using the GeneXpert assay, Sputum smear microscope and chest radiography. However, the culture method is considered as gold standard for detecting the causative agent of tuberculosis, Mycobacterium tuberculosis, but it is a time-consuming diagnosis with substantial contamination risks.⁽¹⁰⁾

Pyrrrole is a five membered heterocyclic ring system has a fundamental role in living world. Pyrrrole is unstable towards mineral acids, and is protonated in the second position. The resulting Pyrrylium cation polymerizes very readily to give high molecular mass pyrrrole resins because of its high-electron density, the characteristic reactions of Pyrrrole are electrophilic substitution.⁽¹¹⁾

Pyrrrole derivatives have been found to possess a wide spectrum of activities, of which anti-TB is one of the prominent one.⁽¹²⁾ Pyrrrole derivatives are found in varieties of biological context as part of co-factor and natural product. Common naturally produced molecules containing pyrrrole includes Vit.B12, bile pigments like bilirubin and biliverdin, porphyrins of heme, chlorophyll, chlorins, bacteriochlorins and porphyrinogens. One of the first synthesis of pyrrrole containing molecule was that of haemin synthesized by E. Fischer in 1929.⁽¹³⁾

Chemistry

Apparatus: Round bottom flask, Condenser, Magnetic stirrer, Measuring cylinder, Beaker, Boiling chips, Petri dish, Glass Rod

Chemicals Required: Ethyl-4-aminobenzoate, 2,5-dimethoxy tetrahydrofuran, Glacial acetic acid, Hydrazine Hydrate, Ethanol, substituted aldehydes, thioglycolic acid, benzene, sodium bicarbonate, 2,3-Dimethoxybenzaldehyde, vanillin, anisaldehyde. Ethyl acetate : Chloroform in the ratio 7 : 3 & Ethyl acetate : petroleum ether in the ratio 6 : 4 for TLC

Software's- Chemdraw Professional 16.0, Chem 3D 16.0, PyRx, Discovery studio

Method:

➤ Step-1 General procedure for synthesis of ethyl 4-(1H-pyrrol-1-yl) benzoate(I):

Compound (I) was synthesized by refluxing a mixture of ethyl 4-aminobenzoate (0.05 mol) in glacial acetic acid (7.5ml) and 2,5-dimethoxy tetrahydrofuran (0.05 mol) at 150-160⁰ C for 45 min. Then the reaction mixture was poured onto crushed ice further it was neutralized with saturated solution of sodium bicarbonate, the separated solid was filtered and recrystallized with ethanol.

➤ **Step-2 Procedure for the synthesis of 4-(1H-pyrrol-1-yl) benzohydrazide (II):**

Compound (II) was synthesized by refluxing a mixture of ethyl-4-(1H-pyrrol-1-yl) benzoate (I) (0.014 mol) with hydrazine hydrate (9.3ml) in absolute ethanol (9.3ml) for 3hr then reaction mixture was cooled. The obtained crystalline mass was filtered and recrystallized with ethanol.

➤ **Step-3 General synthesis of Schiff base derivatives of pyrrole (III):**

Compound (III) was then synthesized by dissolving aromatic aldehyde (10mol) was dissolved in ethanol and was treated with a solution of benzoic acid hydrazide (10mol) or phenolic acid hydrazide (10mmol) in ethanol (25ml), followed by three drops of glacial acetic acid. The reaction mixture was then cooled down to ambient temperature and the resulting precipitate was filtered off by gravity filtration, dried and recrystallized from ethanol to give products.

➤ **Step-4 Synthesis of Pyrrolyl Thiozolidinone Derivative (IV):**


To a solution of Schiff base, To compound (III) add 0.9 ml of thioglycolic acid and 15 ml of benzene, the mixture was refluxed on the water bath for 8-12hrs then cooled. The Upper organic layer was washed with sodium hydrogen carbonate solution NaHCO_3 and then with water, the Benzene was distilled off then the compound (VI) i.e Pyrrolyl thiazolidinone derivative was synthesized.

Biological Activity

To the newly synthesized compounds with the MIC value was determined against *M. tuberculosis* strains H37 using Microplate Alamar Blue Assay (MABA) using isoniazid as the standard drug. The 96 wells plate received 100 μl of Middlebrook 7H9 broth and serial dilution of compounds were made directly on the plate with drug concentration of 0.2, 0.4, 0.8, 1.6, 3.125, 6.25, 12.5, 25, 50 and 100 $\mu\text{g/ml}$. Plate were covered and sealed with parafilm and incubated at 37°C for 5 days. Then, 25 μl of freshly prepared 1:1 mixture of almar blue reagent and 10% Tween 80 was added in the well was interpreted as no bacterial growth and pink colour in the was scored as growth. The MIC was defined as the lowest drug concentration, which prevented colour change from blue to pink. Compounds 3c, 3g and 3j showed significant antitubercular activity. Table-3 reveals antitubercular activity (MIC) data for all the synthesized compounds


In-Silico Studies

The synthesized compounds were evaluated using molecular docking study software such as chemdraw Professional, chem3D 16.0, PyRx and Discovery studio. Based on the literature review (Decaprenylphosphoryl-beta-D-ribose oxidase of organism *Mycobacterium tuberculosis* H37Rv strain) 6G83 strains was selected and downloaded from RCSB-Protein Data Bank (PDB). By using chemdraw and chem3D the ligand was prepared. Furthermore by using PyRx software the docking of protein and synthesized ligand molecule was performed, where the binding affinity of each synthesized compound was found and then the docked structure of protein-ligand complex was obtained. Visualization of Docked structure was done using Discovery Studio



Results and discussion

Compound III (Pyrrolyl Schiff base derivatives) was synthesized and melting point is was found to be 215⁰c-220⁰c



Compound IV (Pyrrolyl thiazolidinone derivatives) was synthesized and melting point is as follows;

Table no-1(Physicochemical data of compound III)

comp	R	Melting Point	Molecular Formula	Molecular weight	RF Value
4a	 vanillin	180 ⁰ C	C ₂₁ H ₁₇ N ₃ O ₄ S	407	0.772
4b	 3,4-dimethoxy benzaldehyde	187 ⁰ C	C ₂₂ H ₁₉ N ₃ O ₄ S	421	0.80
4c	 Anisaldehyde	184 ⁰ C	C ₂₁ H ₁₇ N ₃ O ₃ S	391	0.82

Mobile phase: For compound 4a,4c. Ethylacetate: Chloroform (7:3); for 4b- Ethylacetate : n-petroleum ether (6:4) and Detecting agent: Iodine Chamber.

The Spectral Data of The Newly Synthesized Pyrrole Derivatives(4a-c)

- **FT-IR spectrum of 4a:** 3205-90(-NH stretching); 2918.74(-CH stretching); 1685.81(-C=O stretching); 1512.94(-C=C stretching); 1278.64(-C-N stretching)

¹H NMR (DMSO) 500MHz (δppm)(4a): 3.7-3.8(s 3H,-CH); 4.1(d 1H,Ar-CH); 6.0(s 1H,Ar-CH); 6.35-6.38(s 3H,Pyrrole); 6.8(s 1H,Pyrrole); 6.9(d 2H,Pyrrole); 7.0-7.8(d 5H,Ar-CH); 8.4(s 1H,OH)

- **FT-IR spectrum of 4b:** 3251.62(-NH stretching); 2920.17(-CH stretching); 1641.52(-C=O stretching); 1507.23(-C=C stretching); 1327.22(-CN stretching)

¹H NMR(CDCl₃) 500MHz (δ ppm) 4b: 2.0-2.3(m 6H, CH); 3.9(d 1H,CH); 6.3(s 1H,Pyrrole); 7.1(s 2H,Ar-CH); 7.2(d 2H,Pyrrole); 7.3(t 2H,Ar-CH); 7.5(d 2H,Ar-CH); 7.6(d 2H,Ar-CH); 9.9(s 1H,NH)

¹³C NMR(CDCl₃) 500MHz (δ ppm) 4b: 150.1(C₂₄ of terminal benzene), 149.5(C₂₄ of terminal benzene), 143.7(C₆ of bridged benzene), 128.9-129.2(C₉ of bridged benzene), 121.4(C₁,C₂ of Pyrrole), 118.9(C₂₆ of terminal benzene), 111.1(C₂₃ of terminal benzene), 110.4(C₂,C₃ of Pyrrole), 56.05(C₃₀, C₂₈ of aliphatic compounds)

Mass Spectral Data: Molecular Weight of the Compound 4b is 446 m/z

- **FT-IR spectrum of 4c:** 3217.33(-NH stretching); 2918.74(-CH stretching); 1717.24(-C=O stretching); 1510.09(-C=C stretching); 1327.22(-CN stretching)


¹H NMR(CDCl₃) 500MHz (δ ppm)4c: 0.8(s 2H,CH); 1.2(s 8H,CH); 3.7(d 2H,CH); 6.3(s 1H,Pyrrole); 7.0(s 1H,); 7.2-7.4(d 2H,Ar-CH); 7.7(d 1H,Ar-CH)

Table No:6; Screening of Anti-tubercular activity by MABA method for newly synthesized compounds


Compounds	MIC µg/mL
4a	125µg/mL
4b	62.5µg/mL
4c	125µg/mL
Rifampicin	0.98µg/mL
Isoniazid	1.95µg/mL

Table No :5; Binding Affinity of Docked Ligand

Compound	Binding Affinity	Mode	RMSD/Lb	RMSD/Ub
4a	-5.4	0	0.0	0.0
4b	-6.2	0	0.0	0.0
4c	-5.1	0	0.0	0.0

Anti-tubercular activity result of compound (4a-c)**Fig no-02**

Compared with Standard [Rifampicin and Isoniazid] [fig;4]

**Fig no-03**

Newly Synthesized compounds(4a-c) were tested for antitubercular activity using MABA method against H37Rv strain. The compound 4b shows good anti-tubercular activity with MIC value of 62.5µg/mL are shown in the Table no-6

Molecular docking study for newly synthesized derivatives(4a-c)

By doing literature study, the crystal structure of protein Decaprenylphosphoryl-beta-D- ribose oxidase)6G83^[14] was downloaded from Protein Data Base [PDB]




Fig no- 04 & 05





Fig no-06 (3D& 2D) structure of compound 4a





Fig no-07 (3D& 2D) structure of compound 4b





Fig no-08 (3D& 2D) structure of compound 4c

**Boiled EGG
model**




Fig no-09 (4a)




Fig no-10(4b)




Fig no-11(4c)

In this research work, by the reaction between ethyl-4-aminobenzoate and 2,5-dimethoxy tetrahydrofuran in dried acetic acid the compound(I) was synthesized, The synthesized compound (1) was then reacted with hydrazine hydrate in absolute ethanol to yield the compound (2), the compound (2) in the presence of aromatic aldehyde and ethanol which was refluxed for 3hr yields the compound (3), Further the compound (3) was refluxed in the presence of thioglycolic acid and benzene for 12hrs to yield the compound(4a-c).

The Physicochemical data of newly synthesized Pyrrolyl thiazolidinone derivatives(4a-c) given in table no-01 where the purity of the synthesized compound was confirmed and then the synthesized compound 4a-c subjected for spectral characterization data such as FT-IR, ¹H NMR, ¹³C NMR and mass spectroscopy.

Antitubercular activity of the synthesized compound was carried out using *Mycobacterium tuberculosis* H₃₇Rv strain using the Microplate Alamar Blue Assay (MABA) method. The compound 4b exhibit good antitubercular activity with MIC value of 62.5µg/ml, And the compound 4a and 4c shows moderate activity with the MIC value of 125µg/ml when compared with the standard drugs isoniazid and rifampicin.

Further, In-silico studies were carried out using software Discovery studio and PyRx, which provides the data about the binding affinity for the docked ligand for the compound (4a-d) in which the compound 4b shows the good binding affinity of value of -6.2 against the target protein Decaprenylphosphoryl-beta-D-ribose oxidase(6G83), were as the compound 4a, 4c and 4d shows the value of -5.4, -5.1 and -5.8.

The boiled egg model was also studied and observed to know the lipophilicity and hydrophilicity of the synthesized compounds, from which we got to know that all the synthesized compounds were hydrophilic in nature.

Conclusion

A novel series of Pyrrolyl thiazolidinone derivatives were synthesized by the reaction between Pyrrolyl Schiff Base in the Presence thioglycolic acid and benzene which was refluxed for 12hr to obtain Pyrrolyl thiazolidinone derivative (4a-c).The synthesized compound were characterized by the spectroscopic techniques such as FT-IR, ¹H NMR, ¹³C NMR and mass spectra. The synthesized compound further screened for the antitubercular activity against *Mycobacterium tuberculosis* H₃₇Rv strain using the Microplate Alamar Blue Assay (MABA) method by using standard drug as rifampicin and isoniazid. The compound 4b shows good anti-tubercular activity with MIC value of 62.5µg/ml and the compound 4a and 4c shows the moderate activity with MIC value of 125µg/ml. Further, In-silico studies were carried out using software PyRx and Discovery studio, which provides the data about the binding affinity for the docked ligand, for the compound 4a-d in which the compound 4b shows the good binding affinity of value of -6.2 against the target molecule of Decaprenylphosphoryl-beta-D-ribose oxidase(6G83), were as the compound 4a, 4c and 4d shows the value of -5.4,-5.1 and -5.8. Through boiled egg model we can also conclude that all compounds are hydrophilic in nature.Hence, we conclude that this study will serve as a valuable guide for the further, design and synthesis of more effective pyrrole derivatives for the treatment of tuberculosis.

References:

1. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption- A review on tuberculosis. Mem. Inst. Oswaldo Cruz 101(7), 697- 714 (2006).
2. Katherine A Sacksteder, Marina Protopopova, Clifton E Barry, Koen Andries, Carol A Nacy. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. (2012) 7(7), 823–837.
3. S.D. Joshi. A novel class of potential antibacterial and antitubercular agent. European Journal of Medicinal Chemistry 43(2008) 1989-1996.
4. Goverdhan Surineni, Perumal Yogeewari, Dharmarajan Sriram, Srinivas Kantevari. Design and synthesis of novel carbazole tethered pyrrole derivatives as potent inhibitors of Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters 25 (2015) 485-491.
5. Théoneste Umumararungu, Marie Jeanne Mukazayire. A review of recent advances in anti-tubercular drug development. Indian Journal of Tuberculosis, 15 July 2020.
6. Tarek Aboul-Fadl, Fayzah A. S. Bin-Jubair. Anti-Tubercular Activity of Isatin Derivatives. Int. J. Res. Pharm. Sci. Vol-1, Issue-2, 113-126, 2010
7. Shrinivas D Joshi. Synthesis and molecular modeling studies of novel pyrrole analogs as antimycobacterial agents, Journal of Saudi Chemical Society(2017) 21,42-57.
8. Shahinda S.R, Alsayed. Pathogenesis, Current Treatment Regimens and New Drug Targets, International Journal of Molecular Sciences(2023) 24,5202.
9. Won EJ, Choi JH, Cho YN, Jin HM, Kee HJ, Park YW, et al. Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease. Journal of Infection. 2017;74(3):281–93.
10. Khan MT, Kaushik AC, Ji L, Malik SI, Ali S, Wei DQ. Artificial neural networks for prediction of tuberculosis disease. Frontiers in Microbiology. 2019;10(Mar):1–9.
11. Harreus, Albrecht Ludwig. "Pyrrole". *Ullmann's Encyclopedia of Industrial Chemistry*. Weinheim: Wiley-VCH
12. Rikta Saha, Md. Mumtaz Alam, Mymoona Akhter. Novel Hybrid-Pyrrole Derivatives: Their Synthesis, Antitubercular Evaluation and Docking Studies. The Royal Society of Chemistry, 19 Dec 2014.
13. Somnath S. Gholap. Pyrrole: An emerging scaffold for construction of valuable therapeutic agents, European Journal of Medicinal Chemistry 110 (2016) 13-31
14. U Usha Rani, A Sreedevi. Synthesis and Biological Evaluation of 3-(2-Benzoyl-4-chlorophenyl)-4H-spiro [indole-3,2-[1,3]thiazolidine]-2,4(1H)- dione Derivatives for Anti-tubercular and Antimicrobial Activities. / Indian Journal of Science and Technology ,2024, 17(20),2101–2109.